Patents Assigned to AnorMED, Inc.
-
Patent number: 7452994Abstract: This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.Type: GrantFiled: November 14, 2006Date of Patent: November 18, 2008Assignee: Anormed, Inc.Inventors: Ernest J. McEachern, Gary J. Bridger, Krystyna A. Skupinska, Renato T. Skerlj, Wen Yang
-
Patent number: 7354934Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).Type: GrantFiled: December 13, 2005Date of Patent: April 8, 2008Assignee: Anormed, Inc.Inventors: Gary J. Bridger, Al Kaller, Curtis Harwig, Renato T. Skerlj, David Bogucki, Trevor R. Wilson, Jason B. Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria R. Di Fluri
-
Patent number: 7354932Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).Type: GrantFiled: June 6, 2003Date of Patent: April 8, 2008Assignee: Anormed, Inc.Inventors: Gary Bridger, Al Kaller, Curtis Harwig, Renato Skerlj, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
-
Patent number: 7332605Abstract: This invention relates to a process for synthesizing heterocyclic pharmaceutical compound which binds to the CXCR4 chemokine receptor.Type: GrantFiled: March 11, 2005Date of Patent: February 19, 2008Assignee: AnorMED, Inc.Inventors: Jason B. Crawford, Gang Chen, David Gauthier, Renato Skerlj, Ian R. Baird, Trevor R. Wilson
-
Publication number: 20070066624Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).Type: ApplicationFiled: August 16, 2006Publication date: March 22, 2007Applicant: AnorMED, Inc.Inventors: Yuanxi Zhou, Elyse Bourque, Yongbao Zhu, Ernest McEachern, Curtis Harwig, Renato Skerlj, Gary Bridger, Tong-Shuang Li, Markus Metz
-
Publication number: 20070060757Abstract: This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.Type: ApplicationFiled: November 14, 2006Publication date: March 15, 2007Applicant: AnorMED Inc.Inventors: Ernest McEachern, Gary Bridger, Krystyna Skupinska, Renato Skerlj, Wen Yang
-
Patent number: 7183273Abstract: Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCR4 receptor.Type: GrantFiled: April 30, 2004Date of Patent: February 27, 2007Assignee: AnorMED, Inc.Inventors: Gary J. Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
-
Patent number: 7169750Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z? ??(1) or pharmaceutically acceptable salt thereof wherein Z is of the formula wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1–20 atoms, Z? is of the formula —Ar(Y)j; wherein Ar is an aromatic or heteroaromatic moiety, and each Y is independently a non-interfering substituent and j is 0–3; and “linker” represents a bond, alkylene (1–6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.Type: GrantFiled: June 5, 2003Date of Patent: January 30, 2007Assignee: Anormed, Inc.Inventors: Gary Bridger, Michael J. Abrams, Geoffrey W. Henson, Ronald T. MacFarland, Gary B. Calandra
-
Patent number: 7160872Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.Type: GrantFiled: June 21, 2004Date of Patent: January 9, 2007Assignee: AnorMED Inc.Inventors: Gary Bridger, Eva Maria Boehringer, Zhongren Wang, Dominique Schols, Renato Skerlj, David Bogucki
-
Publication number: 20060264434Abstract: This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines.Type: ApplicationFiled: July 27, 2006Publication date: November 23, 2006Applicant: AnorMED Inc.Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor Wilson, Jason Crawford, Ernest McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
-
Patent number: 7135570Abstract: This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)— and (S)— forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)— or (S)— enantiomer of primary amino-substituted fused bicyclic ring systems.Type: GrantFiled: October 6, 2004Date of Patent: November 14, 2006Assignee: Anormed Inc.Inventors: Ernest J. McEachern, Gary J. Bridger, Krystyna A. Skupinska, Renato T. Skerlj, Wen Yang
-
Publication number: 20060193826Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.Type: ApplicationFiled: November 8, 2005Publication date: August 31, 2006Applicant: AnorMED Inc.Inventors: Gary Bridger, Michael Abrams, Geoffrey Henson, Ronald MacFarland, Gary Calandra, Hal Broxmeyer, David Dale
-
Patent number: 7091217Abstract: Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.Type: GrantFiled: March 11, 2004Date of Patent: August 15, 2006Assignee: AnorMED, Inc.Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
-
Patent number: 7022717Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.Type: GrantFiled: November 7, 2003Date of Patent: April 4, 2006Assignee: AnorMED, Inc.Inventors: Gary James Bridger, Eva Maria Boehringer, Zhongren Wang, Dominique Schols, Renato Tony Skerlj, David Earl Bogucki
-
Patent number: 6987102Abstract: Certain nitrogen-containing compounds that bind the chemokine receptor CXCR4 are able to mobilize progenitor and/or stem cells into the peripheral blood to permit harvesting them for stem cell transplantation.Type: GrantFiled: July 30, 2002Date of Patent: January 17, 2006Assignee: Anormed, Inc.Inventors: Gary J. Bridger, Michael J. Abrams, Geoffrey W. Henson, Ronald Trevor MacFarland, Gary B. Calandra, Hal E. Broxmeyer, David C. Dale
-
Patent number: 6894049Abstract: The present invention relates to platinum antitumor drugs. In particular, it relates to platinum complexes having formula Ia or Ib or a pharmaceutically acceptable salt thereof wherein: each A is independently an anion; each B is independently halo, hydroxy, carboxylate, carbamate or a carbonate ester, Z is a substituted 5- or 6-membered, heterocyclic moiety wherein at least one substituent sterically hinders access of the Pt atom to a DNA strand of a tumor cell, and wherein Z is other than pyridine; and X is NH3 or mono- or dialkyl substituted NH3. which are active against cancer cells and have improved aqueous solubility and activity.Type: GrantFiled: October 4, 2000Date of Patent: May 17, 2005Assignee: AnorMED, Inc.Inventors: Ernest S. Y. Wong, Christen M. Giandomenico
-
Publication number: 20050080267Abstract: This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.Type: ApplicationFiled: October 6, 2004Publication date: April 14, 2005Applicant: AnorMED, Inc.Inventors: Ernest McEachern, Gary Bridger, Krystyna Skupinska, Renato Skerlj
-
Patent number: 6872714Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that medicate a number of mammalian embryonic developmental processes.Type: GrantFiled: July 8, 1999Date of Patent: March 29, 2005Assignee: AnorMed Inc.Inventor: Dominique Schols
-
Patent number: 6864265Abstract: Compounds that bind to chemokine receptors such as CXCR4 and CCR5 demonstrate protective effects against infection of cells by human immunodeficiency virus are disclosed. These compounds contain a tertiary amine[[s]] linked to a core nitrogen via an aromatic or heteroaromatic moiety.Type: GrantFiled: September 17, 2001Date of Patent: March 8, 2005Assignee: AnorMED, Inc.Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. Mceachern, Bern Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis, Rosaria Maria Di Fluri
-
Patent number: 6835731Abstract: Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.Type: GrantFiled: September 17, 2001Date of Patent: December 28, 2004Assignee: AnorMED, Inc.Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis, Rosaria Maria Di Fluri